Nilotinib is a common drug used in imatinib-resistant or imatinib-intolerant CML, and it is recommended to test for the genetic variant associated with nilotinib-induced hyperbilirubinemia, such as UGT1A1*28 and UGT1A1*6, ahead of nilotinib administration [23,24,25,26]. Here, UGT1A1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.